Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLOLAN vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Epoprostenol is a prostaglandin I2 (prostacyclin) analogue that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and has antiproliferative effects on vascular smooth muscle.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Pulmonary arterial hypertension (PAH) (WHO Group I) in NYHA Class III-IV patients to improve exercise capacity and hemodynamics,Pulmonary arterial hypertension in patients who require chronic IV therapy,Off-label: Severe Raynaud's phenomenon, primary pulmonary hypertension in neonates, and as a bridge to lung transplantation
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
Initial: 4 ng/kg/min via continuous IV infusion, then titrated in increments of 1-2 ng/kg/min at intervals of at least 15 minutes based on clinical response. Typical maintenance dose: 20-40 ng/kg/min; range: 10-80 ng/kg/min.
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
3–5 minutes (terminal elimination half-life; rapid inactivation necessitates continuous IV infusion).
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
Epoprostenol undergoes rapid hydrolysis at neutral p H and is also metabolized by enzymes including 15-hydroxyprostaglandin dehydrogenase to inactive metabolites (6-keto-PGF1alpha, 6,15-diketo-PGF1alpha, and 6,15-diketo-13,14-dihydro-PGF1alpha).
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Renal: 70% (as inactive metabolites); biliary/fecal: negligible.
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
Approximately 50% bound to albumin.
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
0.03–0.1 L/kg; small Vd consistent with limited extravascular distribution.
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Intravenous: 100% (only route of administration).
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
No specific dose adjustment required; monitor fluid and electrolyte balance due to potential hypotension.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
No specific dose adjustment required; consider reduced clearance in severe hepatic impairment (Child-Pugh class C) with cautious titration.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
Initial: 2 ng/kg/min via continuous IV infusion, titrate by 1-2 ng/kg/min every 15 minutes as tolerated. Maximum dose not established; typical range 5-40 ng/kg/min.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
No specific dose adjustment; start at lower end of dosing range (4 ng/kg/min) and titrate cautiously due to increased sensitivity to hemodynamic effects.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
FLOLAN is a potent vasodilator and must be administered by continuous IV infusion through a permanent central venous catheter. Abrupt discontinuation or sudden large dose reductions may result in worsening pulmonary hypertension and death. Only clinicians experienced in PAH treatment should prescribe FLOLAN.
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Do not abruptly discontinue infusion (risk of rebound pulmonary hypertension), monitor for pulmonary edema (if suspect veno-occlusive disease), may cause bleeding complications (due to antiplatelet effects), monitor for sepsis/thrombosis from chronic IV catheter, use caution in patients with hepatic or renal impairment.
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
Long-term use in patients with pulmonary veno-occlusive disease (PVOD), hypersensitivity to epoprostenol or structurally related drugs, or severe left ventricular systolic dysfunction (NYHA Class III-IV heart failure) due to risk of pulmonary edema.
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
No specific food interactions are reported for epoprostenol. Avoid excessive alcohol as it may worsen hypotension.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; however, no adequate and well-controlled studies in pregnant women. Epoprostenol is a potent vasodilator and inhibitor of platelet aggregation; theoretical risk of hemorrhage in the fetus. Use only if clearly needed.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
Epoprostenol is not recommended during breastfeeding. No data on presence in human milk, effects on the breastfed infant, or milk production. Due to potential for serious adverse reactions (e.g., hypotension, bleeding), breastfeeding should be discontinued during treatment.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
Pregnancy may alter pharmacokinetics; increase in plasma volume may require dose adjustments. No formal studies; titrate dose based on clinical response (e.g., symptoms of pulmonary arterial hypertension). Monitor for signs of overdose (hypotension, tachycardia) or underdose (worsening dyspnea).
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
FLOLAN (epoprostenol) is a prostacyclin used for pulmonary arterial hypertension (PAH). It has a very short half-life (3-5 minutes) and must be administered via continuous IV infusion. Abrupt interruption can cause life-threatening rebound pulmonary hypertension. The drug is unstable at room temperature; requires ice packs during administration. Dose titration is done based on symptoms and side effects (e.g., jaw pain, flushing, headache, diarrhea).
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
This medication is given continuously through an intravenous (IV) line using a portable infusion pump.,Never stop the infusion suddenly; sudden stoppage can cause severe worsening of your condition.,Keep the medication cold (with ice packs) during infusion; it degrades at room temperature.,Report any signs of infection at the IV site, such as redness, swelling, or pain.,Common side effects include headache, jaw pain, flushing, nausea, and diarrhea; these may improve over time.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLOLAN vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, answered by our medical review team.
FLOLAN is a Prostacyclin Vasodilator that works by Epoprostenol is a prostaglandin I2 (prostacyclin) analogue that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and has antiproliferative effects on vascular smooth muscle.. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLOLAN and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLOLAN is: Initial: 4 ng/kg/min via continuous IV infusion, then titrated in increments of 1-2 ng/kg/min at intervals of at least 15 minutes based on clinical response. Typical maintenance dose: 20-40 ng/kg/min; range: 10-80 ng/kg/min.. The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLOLAN and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLOLAN is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; however, no adequate and well-controlled studies in pregnant women. Epoprostenol is a potent vasodilator . ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.